Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 2013 International Congress of Parkinson’s …

JERUSALEM--(BUSINESS WIRE)--

Teva Pharmaceutical Industries Ltd. (TEVA) announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinsons Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society (MDS). These presentations affirm Tevas ongoing commitment to Parkinsons disease (PD) research and underscore the potential of AZILECT as a treatment modality for PD.

The AZILECT abstract topics presented at MDS demonstrate our efforts to further clarify the clinical utility of rasagilineto prescribers and PD patients across various stages of the disease, said Michael Hayden, MD, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. We are committed to driving advances in research to help address the treatment needs of those impacted by neurological conditions.

Some of the presentations include:

ABOUT AZILECT (UNITED STATES)

AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.

Patients should not take AZILECT if they are taking meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. Johns Wort, cyclobenzaprine, or other monoamine oxidase inhibitors (MAOIs), as it could result in a serious reaction. Patients should inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin. Patients with moderate to severe liver disease should not take AZILECT. Patients should not exceed a dose of 1 mg per day of AZILECT in order to prevent a possibly dangerous increase in blood pressure.

Side effects seen with AZILECT alone are flu syndrome, joint pain, depression, and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesia), accidental injury, weight loss, low blood pressure when standing, vomiting, anorexia, joint pain, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.

See additional important information at http://www.azilect.com/Resources/PDFs/PrescribingInformation-pdf.aspx. For hardcopy releases, please see enclosed full prescribing information.

AZILECT is currently available in more than 40 countries worldwide, including the U.S., Canada, Israel, Mexico, and all EU countries. Teva has a long-term agreement for the joint development and marketing of AZILECT in Europe and some additional markets with H. Lundbeck A/S. In North America, AZILECT is marketed by Teva's wholly-owned subsidiary, Teva Neuroscience, Inc. (www.tevaneuro.com).

Read the original here:
Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 2013 International Congress of Parkinson’s ...